Systemic Amyloidosis in England: An epidemiological study

British Journal of Haematology

Volumn 161, Issue 4, 2013, Pages 525-532

  Pinney, Jennifer H ^a   Smith, Colette J ^b   Taube, Jessi B ^a   Lachmann, Helen J ^a   Venner, Christopher P ^a   Gibbs, Simon D J ^a   Dungu, Jason ^a   Banyperasad, Sanjay M ^a   Wechalekar, Ashutosh D ^a   Whelan, Carol J ^a   Hawkins, Philip N ^a   Gillmore, Julian D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloidosis; Death certificate; Incidence; Survival

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; AMYLOIDOSIS; ARTICLE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH CERTIFICATE; EPIDEMIOLOGICAL MONITORING; FAMILIAL AMYLOIDOSIS; GEOGRAPHIC DISTRIBUTION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; INFANT; INTESTINE PERFORATION; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE ORGAN FAILURE; MYELOMA; NEPHROTIC SYNDROME; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; SEPSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; ENGLAND; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84876789377     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12286     Document Type: Article

References (14)

1. Cotch, M.F., Hoffman, G.S., Yerg, D.E., Kaufman, G.I., Targonski, P. & Kaslow, R.A. (1996) The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis and Rheumatism, 39, 87-92.
2. Gillmore, J.D., Stangou, A.J., Lachmann, H.J., Goodman, H.J., Wechalekar, A.D., Acheson, J., Tennent, G.A., Bybee, A., Gilbertson, J., Rowczenio, D., O'Grady, J., Heaton, N.D., Pepys, M.B. & Hawkins, P.N. (2006) Organ transplantation in hereditary apolipoprotein AI amyloidosis. American Journal of Transplantation, 6, 2342-2347.
3. Gillmore, J.D., Lachmann, H.J., Rowczenio, D., Gilbertson, J.A., Zeng, C.H., Liu, Z.H., Li, L.S., Wechalekar, A. & Hawkins, P.N. (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. Journal of the American Society of Nephrology, 20, 444-451.
4. Imaizumi, Y. (1989) Mortality rate of amyloidosis in Japan: secular trends and geographical variations. American Journal of Medical Genetics, 34, 562-568.
5. Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., Marinaki, S., Apostolou, T., Nikitas, N., Gkortzolidis, G., Michalis, E., Delimpasi, S. & Dimopoulos, M.A. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 119, 5384-5390.
6. Kumar, S., Dispenzieri, A., Lacy, M., Hayman, S., Buadi, F., Detweiler-Short, K., Zeldenrust, S., Leung, N., Dingli, D., Greipp, P., Lust, J., Russell, S., Kyle, R., Rajkumar, V. & Gertz, M. (2010) Improved survival in light chain amyloidosis. Amyloid-Journal of Protein Folding Disorders, 17, 89-90.
7. Kyle, R.A., Linos, A., Beard, C.M., Linke, R.P., Gertz, M.A., O'Fallon, W.M. & Kurland, L.T. (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 79, 1817-1822.
8. Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Pepys, M.B. & Hawkins, P.N. (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New England Journal of Medicine, 346, 1786-1791.
9. Lachmann, H.J., Goodman, H.J.B., Gilbertson, J.A., Gallimore, J.R., Sabin, C.A., Gillmore, J.D. & Hawkins, P.N. (2007) Natural history and outcome in systemic AA amyloidosis. New England Journal of Medicine, 356, 2361-2371.
10. Marin, B., Couratier, P., Preux, P.M. & Logroscino, G. (2011) Can mortality data be used to estimate amyotrophic lateral sclerosis incidence? Neuroepidemiology, 36, 29-38.
11. Pepys, M.B. (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 356, 203-211.
12. Simms, R.W., Prout, M.N. & Cohen, A.S. (1994) The epidemiology of AL and AA amyloidosis. Baillieres Clinical Rheumatology, 8, 627-634.
13. Thomas, S.L., Griffiths, C., Smeeth, L., Rooney, C. & Hall, A.J. (2010) Burden of mortality associated with autoimmune diseases among females in the United Kingdom. American Journal of Public Health, 100, 2279-2287.
14. Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., Whelan, C.J., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. & Wechalekar, A.D. (2012) Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival. Blood, 119, 4387-4390.